Patents by Inventor Jiamiao WANG

Jiamiao WANG has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Powder injection of the donepezil semi palmoxiric acid salt, composition containing same and preparation method therefor
    Patent number: 11801239
    Abstract: A powder injection of a donepezil semi palmoxiric acid salt, a composition containing the same and a preparation method therefor. The powder injection contains donepezil semi palmoxiric acid salt crystals having an average particle size of 2-52 ?m.
    Type: Grant
    Filed: November 10, 2021
    Date of Patent: October 31, 2023
    Assignees: Shanghai Synergy Pharmaceutical Sciences Co., Ltd., Zhejiang Huahai Pharmaceutical Co., Ltd.
    Inventors: Jian Ge, Yunfei Li, Lihong Lin, Dengxue Sun, Jiamiao Wang, Yijin Wang, Zhiyun Wang
  • POWDER INJECTION OF THE DONEPEZIL SEMI PALMOXIRIC ACID SALT, COMPOSITION CONTAINING SAME AND PREPARATION METHOD THEREFOR
    Publication number: 20220062249
    Abstract: A powder injection of a donepezil semi palmoxiric acid salt, a composition containing the same and a preparation method therefor. The powder injection contains donepezil semi palmoxiric acid salt crystals having an average particle size of 2-52 ?m.
    Type: Application
    Filed: November 10, 2021
    Publication date: March 3, 2022
    Applicants: Shanghai Synergy Pharmaceutical Sciences Co., Ltd, Zhejiang Huahai Pharmaceutical Co., Ltd.
    Inventors: Jian GE, Yunfei LI, Lihong LIN, Dengxue SUN, Jiamiao WANG, Yijin WANG, Zhiyun WANG
  • Powder injection of the donepezil semi palmoxiric acid salt, composition containing same and preparation method therefor
    Patent number: 11197850
    Abstract: A powder injection of a donepezil semi palmoxiric acid salt, a composition containing the same and a preparation method therefor. The powder injection contains donepezil semi palmoxiric acid salt crystals, and the average grain size of the crystals ranges from 0.5 ?m to 100 ?m.
    Type: Grant
    Filed: February 13, 2018
    Date of Patent: December 14, 2021
    Assignees: Shanghai Synergy Pharmaceutical Sciences Co., Ltd., Zhejiang Huahai Pharmaceutical Co., Ltd.
    Inventors: Jian Ge, Yunfei Li, Lihong Lin, Dengxue Sun, Jiamiao Wang, Yijin Wang, Zhiyun Wang
  • POWDER INJECTION OF THE DONEPEZIL SEMI PALMOXIRIC ACID SALT, COMPOSITION CONTAINING SAME AND PREPARATION METHOD THEREFOR
    Publication number: 20200108055
    Abstract: A powder injection of a donepezil semi palmoxiric acid salt, a composition containing the same and a preparation method therefor. The powder injection contains donepezil semi palmoxiric acid salt crystals, and the average grain size of the crystals ranges from 0.5 ?m to 100 ?m.
    Type: Application
    Filed: February 13, 2018
    Publication date: April 9, 2020
    Inventors: Jian GE, Yunfei LI, Lihong LIN, Dengxue SUN, Jiamiao WANG, Yijin WANG, Zhiyun WANG
  • Nitric oxide-releasing prodrug molecule of substituted quinazolines
    Patent number: 10456405
    Abstract: Provided are a compound of the formula below, and a pharmaceutically acceptable salt or stereoisomer thereof that can be used for treating cardiovascular diseases and compositions containing the compounds. The compounds, a pharmaceutically acceptable salt or stereoisomer thereof and the compositions can improve lipid metabolism disorders by increasing high-density lipoprotein cholesterol in blood; in addition, the compounds, a pharmaceutically acceptable salt or stereoisomer thereof and the compositions can also release nitric oxide, and reduce the onset risk of cardiovascular diseases by means of relaxing blood vessels, lowering blood pressure, inhibiting platelet adhesion and aggregation and maintaining vascular tension, and thus play an important role in preventing and treating the occurrence and development of cardiovascular diseases.
    Type: Grant
    Filed: September 6, 2016
    Date of Patent: October 29, 2019
    Assignees: ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD, SHANGHAI SYNERGY PHARMACEUTICAL SCIENCES CO., LTD
    Inventors: Jian Ge, Yunfei Li, Zhen Zhang, Yijin Wang, Jiamiao Wang, Tao Cheng
  • NITRIC OXIDE-RELEASING PRODRUG MOLECULE
    Publication number: 20180250305
    Abstract: Provided are a type of compounds that can be used for treating cardiovascular diseases and compositions containing the compounds. The compounds and the compositions can improve lipid metabolism disorders by increasing high-density lipoprotein cholesterol in blood; in addition, the compounds and the compositions can also release nitric oxide, and reduce the onset risk of cardiovascular diseases by means of relaxing blood vessels, lowering blood pressure, inhibiting platelet adhesion and aggregation and maintaining vascular tension, and thus play an important role in preventing and treating the occurrence and development of cardiovascular diseases.
    Type: Application
    Filed: September 6, 2016
    Publication date: September 6, 2018
    Applicants: ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD., SHANGHAI SYNERGY PHARMACEUTICAL SCIENCES CO., LTD
    Inventors: Jian GE, Yunfei LI, Zhen ZHANG, Yijin WANG, Jiamiao WANG, Tao CHENG